1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Sanofi: Aubagio's tolerability profile is key differentiator in light of lacklustre efficacy

 
• By Sarah Nightingale

The recent Phase III results from the TENERE study of Sanofi 's Aubagio (teriflunomide) comparing it with Rebif (interferon beta-1a; Merck Serono) in patients with relapsing forms of multiple sclerosis suggest that the once-daily oral drug's tolerability profile may prove to be its saving grace, say analysts at Datamonitor.

The recent Phase III results from the TENERE study of Sanofi 's Aubagio (teriflunomide) comparing it with Rebif (interferon beta-1a; Merck Serono) in patients with relapsing forms of multiple sclerosis suggest that the once-daily oral drug's tolerability profile may prove to be its saving grace, say analysts at Datamonitor.

The TENERE study showed that the primary endpoints were not distinguishable and that the prevalence of adverse events was similar...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

In Brief: Neurocrine Details New Data For Schizophrenia Drug Moving To Phase III

 
• By Sushmita Panda

Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.

More from Therapeutic Category

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 
• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.